Literature DB >> 436051

Toxic effects of amantadine in patients with renal failure.

T S Ing, J T Daugirdas, L S Soung, H L Klawans, S D Mahurkar, J A Hayashi, W P Geis, J E Hano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 436051      PMCID： PMC1819146     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  The chemotherapy of viral infections.

Authors:  L Weinstein; T W Chang
Journal:  N Engl J Med       Date:  1973-10-04       Impact factor: 91.245

2.  Amantadine toxicity in a patient with renal insufficiency.

Authors:  K F Armbruster; A C Rahn; T S Ing; I S Halper; J H Oyama; H L Klawans
Journal:  Nephron       Date:  1974       Impact factor: 2.847

3.  Absorption, distribution and excretion of amantadine hydrochloride.

Authors:  W E Bleidner; J B Harmon; W E Hewes; T E Lynes; E C Hermann
Journal:  J Pharmacol Exp Ther       Date:  1965-12       Impact factor: 4.030

4.  The toxicologic and pharmacologic properties of amantadine hydrochloride.

Authors:  V G Vernier; J B Harmon; J M Stump; T E Lynes; J P Marvel; D H Smith
Journal:  Toxicol Appl Pharmacol       Date:  1969-11       Impact factor: 4.219

5.  Visual hallucinations and delirium during treatment with amantadine (Symmetrel).

Authors:  J U Postma; W Van Tilburg
Journal:  J Am Geriatr Soc       Date:  1975-05       Impact factor: 5.562

6.  Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

Authors:  G M Pacifici; M Nardini; P Ferrari; R Latini; C Fieschi; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335
  6 in total
  10 in total

1.  The management of neuroleptic-induced CNS effects.

Authors:  B F Hoffman; M V Seeman
Journal:  Can Fam Physician       Date:  1981-10       Impact factor: 3.275

2.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

4.  Treatment of chronic hepatitis C with amantadine.

Authors:  J P Smith
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

5.  Control of influenza: when do I use amantadine?

Authors:  A McCullough
Journal:  Can Fam Physician       Date:  1989-10       Impact factor: 3.275

6.  Amantadine-dyazide interaction.

Authors:  T W Wilson; A H Rajput
Journal:  Can Med Assoc J       Date:  1983-11-01       Impact factor: 8.262

7.  Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.

Authors:  F G Hayden; H E Hoffman; D A Spyker
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 9.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 10.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.